Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB26FATEM
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,013
Award facts
- Contract value 100% obligated
- $3,012.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $3,012.90 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for NUCALA 100 mg/ml auto-injector medication. The delivery order, issued on October 17, 2025, with an ultimate completion date of October 20, 2025, carries no set-aside designation, indicating the award was made through unrestricted federal competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply the Department of Defense's pharmaceutical and medical consumable needs globally.
DMS Pharmaceutical Group, registered in the System for Award Management since 2001, has established itself as a critical supplier within the federal military pharmaceutical supply chain, demonstrating consistent performance across multiple therapeutic categories and product lines. The company's PPV-G GEN V contract, valued at $499,999,999 and extending through December 31, 2036, positions it as a regional prime vendor contractor authorized to fulfill diverse pharmaceutical requirements for military healthcare facilities worldwide. This delivery order for NUCALA, an immunosuppressant biologic agent, exemplifies the company's capability to supply specialized pharmaceutical products essential to Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DB26FATEM?
SPE2DB26FATEM was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 17, 2025.
How much is contract SPE2DB26FATEM worth?
The government has obligated $3,013 on SPE2DB26FATEM.
Is contract SPE2DB26FATEM an order under another contract?
Yes. SPE2DB26FATEM is a delivery order under SPE2DB24D9228, an indefinite delivery contract.
Was contract SPE2DB26FATEM competed?
The extent of competition for SPE2DB26FATEM was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award